Sequenom (SQNM) Sees 2011 Rev Growth of 23%

Sequenom, Inc. (NASDAQ: SQNM) sees total revenue growth of approximately 23 percent year-over-year for 2011, which compares favorably to the consensus.

The company also announced:

• Over 21,000 total prenatal and retinal diagnostic tests were billed during the year.
  
• Sales in the Genetic Analysis business segment were up approximately 6 percent from 2010. (unaudited), each quarter improving over the same period in the prior year.
  
• Positive results following the October 2011 launch of Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 laboratory developed test

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ocean Power Technologies revises fiscal 2026 results after audit
• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance